Medicare Prescription Drug Price Negotiation Act of 2021

Summary

Medicare Prescription Drug Price Negotiation Act of 2021 This bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. Current law prohibits the CMS from doing so.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 18 March 2021

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

2. 18 March 2021

   Introduced

   Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

   Source: IntroReferral

3. 18 March 2021

   Introduced

   Introduced in House

   Source: IntroReferral

4. 18 March 2021

   Introduced

   Introduced in House

   Source: IntroReferral

5. 19 March 2021

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 18 March 2021 · Download file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 18 March 2021

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 18 March 2021

  ViewDownloadOpen at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

• Introduced in House

  summary · EN · 18 March 2021

  Open at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

• Sen. Welch, Peter [D-VT] · D · Sponsor
• Rep. Pocan, Mark [D-WI-2] · D · Sponsor
• Rep. Castor, Kathy [D-FL-14] · D · Sponsor
• Rep. Grijalva, Raúl M. [D-AZ-7] · D · Sponsor
• Rep. Lynch, Stephen F. [D-MA-8] · D · Sponsor
• Sen. Gallego, Ruben [D-AZ] · D · Sponsor
• Rep. Wasserman Schultz, Debbie [D-FL-25] · D · Sponsor
• Rep. Cicilline, David N. [D-RI-1] · D · Sponsor
• Rep. Pingree, Chellie [D-ME-1] · D · Sponsor
• Rep. Ruiz, Raul [D-CA-25] · D · Sponsor
• Rep. McCollum, Betty [D-MN-4] · D · Sponsor
• Rep. Maloney, Carolyn B. [D-NY-12] · D · Sponsor
• Rep. Smith, Adam [D-WA-9] · D · Cosponsor
• · hsif00 · Standing
• · hswm00 · Standing

Related records

• related to ← Medicare Buy-In and Health Care Stabilization Act of 2021
• related to ← Medicare Prescription Drug Price Negotiation Act of 2019